CHF56.30
1.08% yesterday
SIX Swiss Exchange, Aug 13, 05:30 pm CET
ISIN
NL0011832936
Symbol
COPN

COSMO Pharmaceuticals Target price 2025 - Analyst rating & recommendation

COSMO Pharmaceuticals Classifications & Recommendation:

Buy
91%
Hold
9%

COSMO Pharmaceuticals Price Target

Target Price CHF103.02
Price CHF56.30
Potential
Number of Estimates 7
7 Analysts have issued a price target COSMO Pharmaceuticals 2026 . The average COSMO Pharmaceuticals target price is CHF103.02. This is higher than the current stock price. The highest price target is
CHF139.65 148.05%
register free of charge
, the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend COSMO Pharmaceuticals to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the COSMO Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the COSMO Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 251.37 143.10
187.54% 43.03%
EBITDA Margin 56.51% 58.39%
23,626.10% 3.32%

6 Analysts have issued a sales forecast COSMO Pharmaceuticals 2025 . The average COSMO Pharmaceuticals sales estimate is

CHF143m
Unlock
. This is
16.62% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF231m 34.80%
Unlock
, the lowest is
CHF96.9m 43.55%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF251m 187.54%
2025
CHF143m 43.03%
Unlock
2026
CHF174m 21.48%
Unlock
2027
CHF154m 11.60%
Unlock
2028
CHF451m 193.81%
Unlock
2029
CHF698m 54.51%
Unlock
2030
CHF899m 28.91%
Unlock
2031
CHF931m 3.50%
Unlock
2032
CHF1.2b 29.29%
Unlock

5 Analysts have issued an COSMO Pharmaceuticals EBITDA forecast 2025. The average COSMO Pharmaceuticals EBITDA estimate is

CHF83.6m
Unlock
. This is
21.65% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF128m 85.69%
Unlock
, the lowest is
CHF41.5m 39.54%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF142m 67,747.62%
2025
CHF83.6m 41.14%
Unlock
2026
CHF73.9m 11.49%
Unlock
2027
CHF102m 37.66%
Unlock
2028
CHF273m 168.09%
Unlock
2029
CHF473m 73.22%
Unlock
2030
CHF636m 34.64%
Unlock
2031
CHF631m 0.87%
Unlock
2032
CHF868m 37.54%
Unlock

EBITDA Margin

2024 56.51% 23,626.10%
2025
58.39% 3.32%
Unlock
2026
42.54% 27.15%
Unlock
2027
66.25% 55.74%
Unlock
2028
60.45% 8.75%
Unlock
2029
67.77% 12.11%
Unlock
2030
70.78% 4.44%
Unlock
2031
67.79% 4.22%
Unlock
2032
72.12% 6.39%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share CHF 7.67 5.68
1,317.46% 25.95%
P/E 9.81

6 Analysts have issued a COSMO Pharmaceuticals forecast for earnings per share. The average COSMO Pharmaceuticals EPS is

CHF5.68
Unlock
. This is
74.77% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
CHF6.68 105.54%
Unlock
, the lowest is
CHF4.17 28.31%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF7.67 1,317.46%
2025
CHF5.68 25.95%
Unlock
2026
CHF1.95 65.67%
Unlock
2027
CHF2.81 44.10%
Unlock
2028
CHF12.81 355.87%
Unlock
2029
CHF22.35 74.47%
Unlock
2030
CHF30.24 35.30%
Unlock
2031
CHF29.96 0.93%
Unlock
2032
CHF41.66 39.05%
Unlock

P/E ratio

Current 17.14 17.22%
2025
9.81 42.76%
Unlock
2026
28.62 191.74%
Unlock
2027
19.79 30.85%
Unlock
2028
4.35 78.02%
Unlock
2029
2.49 42.76%
Unlock
2030
1.84 26.10%
Unlock
2031
1.86 1.09%
Unlock
2032
1.34 27.96%
Unlock

Current COSMO Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
ODDO BHF
Locked
Locked
Locked Jul 03 2025
BERENBERG
Locked
Locked
Locked Jun 30 2025
BERENBERG
Locked
Locked
Locked Mar 31 2025
ODDO BHF
Locked
Locked
Locked Mar 06 2025
H.C. WAINWRIGHT & CO., LLC
Locked
Locked
Locked Jan 09 2025
BERENBERG
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
ODDO BHF:
Locked
Locked
Jul 03 2025
Locked
BERENBERG:
Locked
Locked
Jun 30 2025
Locked
BERENBERG:
Locked
Locked
Mar 31 2025
Locked
ODDO BHF:
Locked
Locked
Mar 06 2025
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
Locked
Jan 09 2025
Locked
BERENBERG:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today